中国P站

The field of molecular pharmaceutics is undergoing rapid advancements, focusing on the intricate relationship between molecular properties and drug delivery strategies. Understanding molecular behavior at the nanoscale is paramount for designing effective pharmaceutical products, encompassing areas such as solubility enhancement, controlled release, and targeted delivery. Physicochemical characterization of active pharmaceutical ingredients (APIs) and excipients is crucial for optimizing formulation performance and ensuring therapeutic efficacy, with techniques like amorphous solid dispersions, lipid-based systems, and polymeric nanoparticles playing a key role in overcoming bioavailability challenges [1].

Advanced analytical techniques are increasingly applied to characterize complex pharmaceutical formulations, particularly amorphous solid dispersions (ASDs). Methods like X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and solid-state nuclear magnetic resonance (ssNMR) are essential for evaluating the physical stability and drug release profiles of ASDs. Processing parameters significantly influence the solid-state properties of the drug and polymer, directly impacting dosage form performance, underscoring the importance of thorough solid-state characterization for successful ASD development and manufacturing [2].

Polymeric nanoparticles are being extensively investigated for targeted drug delivery, with functionalized nanoparticles designed to specifically bind to disease-associated biomarkers. This approach aims to increase drug concentration at the target site while minimizing systemic exposure. Controlling nanoparticle size, surface charge, and drug encapsulation efficiency is vital for optimal therapeutic outcomes, with surface modification strategies employed to achieve active targeting and enhance cellular uptake, providing insights into molecular design principles for effective nanocarriers [3].

Lipid-based drug delivery systems (LBDDS) are a significant strategy for improving the oral bioavailability of poorly soluble drugs. These systems, including self-emulsifying drug delivery systems (SEDDS), self-microemulsifying drug delivery systems (SMEDDS), and solid lipid nanoparticles (SLNs), enhance drug absorption through mechanisms like improved drug solubilization, protection from degradation, and modulation of intestinal transport. Formulation development considerations, such as excipient selection and drug loading, are critical for their successful application [4].

Mesoporous silica nanoparticles (MSNs) are emerging as promising carriers for controlled drug release. The synthesis of MSNs with tunable pore sizes and surface functionalities allows for precise control over drug loading and release kinetics. By altering pore diameter and surface modification, the release profile of various therapeutic agents can be tailored, highlighting the potential of MSNs for advanced drug delivery systems offering sustained or triggered release for improved therapeutic efficacy and patient compliance [5].

Molecular interactions between drugs and polymers are fundamental to the performance of amorphous solid dispersions. Polymer-drug miscibility, hydrogen bonding, and other intermolecular forces significantly influence the physical stability and dissolution rate of amorphous drug systems. Computational modeling and experimental techniques are employed to predict and validate these interactions, emphasizing the critical role of polymer selection based on molecular compatibility for achieving stable and effective ASDs with enhanced bioavailability [6].

Stimuli-responsive drug delivery systems offer targeted release capabilities in response to specific biological cues. Novel hydrogel-based systems can alter their physical properties, such as swelling or degradation, in the presence of particular enzymes or pH variations found in diseased tissues. This targeted release mechanism aims to improve therapeutic outcomes by delivering drugs precisely where and when needed, thereby reducing side effects, with the molecular design of polymers playing a key role in their responsiveness [7].

The crystallization of excipients can significantly impact the stability and performance of solid dosage forms. Different excipients can influence the polymorphic form of the API and its subsequent dissolution characteristics. Advanced solid-state analytical techniques are used to correlate excipient properties with API solid form behavior, underscoring the importance of careful excipient selection and processing to maintain the desired physical form of the drug, ensuring consistent drug product quality and therapeutic efficacy [8].

Formulating biologics for oral administration remains a significant challenge due to enzymatic degradation and poor permeability in the gastrointestinal tract. Strategies such as encapsulation in protective carriers like liposomes and nanoparticles, chemical modification of proteins, and the use of permeation enhancers are being explored. Advancements in oral dosage forms for peptide and protein drugs aim to improve patient convenience and adherence, emphasizing the importance of understanding the molecular stability of biologics during formulation and transit [9].

Co-crystals represent a valuable approach for enhancing the physicochemical properties of poorly soluble drugs. Co-crystallization involves forming a crystalline solid composed of the drug and a co-former molecule, leading to improved solubility, dissolution rate, and stability. The design and characterization of drug co-crystals have demonstrated significant bioavailability improvements compared to the parent drug, with molecular interactions between the drug and co-former being key determinants of successful co-crystal formation and performance [10].

Description

This review delves into the intricate relationship between molecular properties and the formulation strategies employed in drug delivery. It highlights how understanding molecular behavior at the nanoscale is crucial for designing effective pharmaceutical products, focusing on areas like solubility enhancement, controlled release, and targeted delivery. The article underscores the importance of physicochemical characterization of active pharmaceutical ingredients (APIs) and excipients for optimizing formulation performance and ensuring therapeutic efficacy. Key insights include the role of amorphous solid dispersions, lipid-based systems, and polymeric nanoparticles in overcoming bioavailability challenges [1].

This research explores the application of advanced analytical techniques in characterizing complex pharmaceutical formulations, particularly focusing on amorphous solid dispersions (ASDs). It details how techniques like X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and solid-state nuclear magnetic resonance (ssNMR) are essential for understanding the physical stability and drug release profiles of ASDs. The study emphasizes the impact of processing parameters on the solid-state properties of the drug and polymer, which directly influence the performance of the final dosage form. The findings suggest that thorough solid-state characterization is paramount for successful development and manufacturing of ASDs [2].

This article investigates the design and characterization of polymeric nanoparticles for targeted drug delivery. It discusses the synthesis of functionalized nanoparticles that can specifically bind to disease-associated biomarkers, thereby increasing drug concentration at the target site and minimizing systemic exposure. The study highlights the importance of controlling nanoparticle size, surface charge, and drug encapsulation efficiency for optimal therapeutic outcomes. Furthermore, it explores various methods for surface modification to achieve active targeting and enhance cellular uptake. The research provides valuable insights into the molecular design principles for creating effective nanocarriers [3].

This review focuses on the role of lipid-based drug delivery systems (LBDDS) in improving the oral bioavailability of poorly soluble drugs. It elaborates on the different types of LBDDS, including self-emulsifying drug delivery systems (SEDDS), self-microemulsifying drug delivery systems (SMEDDS), and solid lipid nanoparticles (SLNs). The article discusses the underlying mechanisms by which LBDDS enhance drug absorption, such as improved drug solubilization, protection from degradation, and modulation of intestinal transport. Key considerations for formulation development, including excipient selection and drug loading, are also addressed [4].

This study investigates the use of mesoporous silica nanoparticles (MSNs) as carriers for controlled drug release. The authors describe the synthesis of MSNs with tunable pore sizes and surface functionalities, which allows for precise control over drug loading and release kinetics. The research demonstrates how varying the pore diameter and surface modification can tailor the release profile of different therapeutic agents. The work highlights the potential of MSNs for developing advanced drug delivery systems with sustained or triggered release mechanisms, offering improved therapeutic efficacy and patient compliance [5].

This paper examines the molecular interactions between drugs and polymers used in pharmaceutical formulations, particularly for amorphous solid dispersions. It elucidates how polymer-drug miscibility, hydrogen bonding, and other intermolecular forces influence the physical stability and dissolution rate of amorphous drug systems. The study utilizes computational modeling and experimental techniques to predict and validate these interactions. The findings underscore the critical role of polymer selection based on molecular compatibility for achieving stable and effective ASDs with enhanced bioavailability [6].

This research explores the development of stimuli-responsive drug delivery systems that release their cargo in response to specific biological cues. The authors present novel hydrogel-based systems that undergo a change in their physical properties (e.g., swelling or degradation) in the presence of particular enzymes or pH variations found in diseased tissues. This targeted release mechanism aims to improve therapeutic outcomes by delivering drugs precisely where and when they are needed, reducing side effects. The work highlights the molecular design of polymers capable of responding to such stimuli [7].

This study examines the impact of excipient crystallization on the stability and performance of solid dosage forms. It investigates how different excipients can influence the polymorphic form of the active pharmaceutical ingredient (API) and its subsequent dissolution characteristics. The research employs advanced solid-state analytical techniques to correlate excipient properties with API solid form behavior. The findings emphasize the importance of careful excipient selection and processing to maintain the desired physical form of the drug, ensuring consistent drug product quality and therapeutic efficacy [8].

This article reviews the progress in formulating biologics for oral administration, a significant challenge due to enzymatic degradation and poor permeability in the gastrointestinal tract. It discusses various strategies, including encapsulation in protective carriers like liposomes and nanoparticles, chemical modification of proteins, and the use of permeation enhancers. The review highlights advancements in creating oral dosage forms for peptide and protein drugs, aiming to improve patient convenience and adherence. Key insights include the importance of understanding the molecular stability of biologics during formulation and transit [9].

This research focuses on the application of co-crystals in pharmaceutical formulations to enhance the physicochemical properties of poorly soluble drugs. Co-crystallization involves forming a crystalline solid composed of the drug and a co-former molecule, leading to improved solubility, dissolution rate, and stability. The study presents the design and characterization of several drug co-crystals, demonstrating significant improvements in bioavailability compared to the parent drug. It underscores the molecular interactions between the drug and co-former as key determinants of successful co-crystal formation and performance [10].

Conclusion

This compilation of research highlights advancements in pharmaceutical formulation and drug delivery. Key areas explored include the impact of molecular properties on drug delivery strategies, the use of amorphous solid dispersions (ASDs) and lipid-based systems for enhancing bioavailability of poorly soluble drugs, and the development of novel delivery platforms like polymeric nanoparticles, mesoporous silica nanoparticles (MSNs), and stimuli-responsive hydrogels for targeted and controlled release. The importance of solid-state characterization, molecular interactions between drugs and excipients, and excipient-induced changes on drug properties are emphasized. Strategies for oral delivery of biologics and the application of co-crystals for improving drug physicochemical properties are also discussed. Overall, these studies underscore the critical role of molecular understanding and advanced formulation techniques in achieving improved therapeutic efficacy and patient outcomes.

References

1. Alexander TV, Peter JS, Ann MVdM. (2019) .J Mol Pharmaceutics Organ Process Res 7:141-155.

   , ,

2. Chong, S, Zhang, L, Li, X. (2023) .J Control Release 355:350-365.

   , ,

3. Chen, Y, Wang, L, Xie, J. (2022) .Biomater Sci 10:1846-1860.

   , ,

4. Mittal, P, Shukla, V, Raturi, A. (2021) .Pharm Res 38:1-17.

   , ,

5. Zhou, L, Gao, C, Ren, J. (2020) .Nanoscale 12:1901-1917.

   , ,

6. Zhang, J, Wang, X, Zhao, Z. (2023) .Mol Pharm 20:2345-2358.

   , ,

7. Kim, J, Park, M, Lee, S. (2022) .Adv Drug Deliv Rev 184:1121-1140.

   , ,

8. Zhao, W, Chen, L, Wang, J. (2021) .Int J Pharm 595:120015.

   , ,

9. Patil, S, Kale, S, Khade, R. (2023) .Pharmaceutics 15:1-18.

   , ,

10. Sheehan, MC, Zhang, G, Chung, H. (2020) .Cryst Growth Des 20:4781-4795.

    , ,